Myeloproliferative Disorders: Clinical Trials

233 trials for Myeloproliferative Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

134 completed, 30 terminated, 26 unknown, 19 active not recruiting. 233 Phase 3, 25 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3233Completed 134, Terminated 30, Unknown 26, Active not recruiting 19, Recruiting 16, Not yet recruiting 5, Withdrawn 2, Suspended 1
Phase 225Completed 12, Unknown 5, Terminated 4, Not yet recruiting 2, Recruiting 1, Withdrawn 1

Follow Myeloproliferative Disorders: new trials by email Literature Review of Myeloproliferative Disorders trials Research Report on Myeloproliferative Disorders

Trials (filtered) newest first · largest first

All 233 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs
ELVN-001, TKI - Chronic Myeloid Leukemia (CML), Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Phase 3RecruitingEnliven Therapeutics4502026-12-312026-11-18
A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
HS-10382, Imatinib, Dasatinib - Chronic Myeloid Leukemia
Phase 3Not yet recruitingJiangsu Hansoh Pharmaceutical Co., Ltd.4082026-12-012026-10-21
A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera
AG-236, Placebo - Polycythemia Vera
Phase 2 / Phase 3Not yet recruitingAgios Pharmaceuticals, Inc.2452026-11-012026-10-13
A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).
Bomedemstat, Ruxolitinib, Ropeginterferon alfa-2b - Polycythemia Vera
Phase 2 / Phase 3RecruitingMerck Sharp & Dohme LLC3802026-10-292026-11-13
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
Placebo, Elritercept - Myelofibrosis, Anemia
Phase 3RecruitingTakeda3242026-09-102026-11-06
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
INCA033989, Best Available Treatment - Essential Thrombocythemia
Phase 3RecruitingIncyte Corporation4262026-09-082026-11-13
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Pelabresib, Ruxolitinib, Placebo - Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF)
Phase 3RecruitingNovartis Pharmaceuticals4602026-05-272026-11-17
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
Sapablursen, Placebo - Polycythemia Vera
Phase 3RecruitingOno Pharmaceutical Co., Ltd.2502026-05-252026-10-29
Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis
Luspatercept, Control - Luspatercept, Poor Erythroid Engraftment
Phase 2 / Phase 3Not yet recruitingNanfang Hospital, Southern Medical University1962026-05-012026-04-20
TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients
TGRX-678, TKI - Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia - Chronic Phase
Phase 3Not yet recruitingShenzhen TargetRx Co., Ltd.1802026-04-012026-03-24
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
Ropeginterferon alfa-2b, Placebo - Primary Myelofibrosis, Myeloproliferative Neoplasm
Phase 3Active not recruitingPharmaEssentia1602025-07-182026-08-13
Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients With Aspirin Resistance
81-mg aspirin once daily, 81-mg aspirin twice daily - Myeloproliferative Neoplasms (MPN)
Phase 3RecruitingSiriraj Hospital2402024-12-122024-12-27
Platelet Transfusion in Critically Ill Patients With Thrombocytopenia
Platelet transfusion if platelet count ≤ 10 G/L, Platelet transfusion when platelet count ≤ 20 G/L - Thrombocythemia
Phase 3Not yet recruitingAssistance Publique - Hôpitaux de Paris5362024-11-012024-09-19
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
Bomedemstat, Hydroxyurea, Bomedemstat placebo - Essential Thrombocythemia
Phase 3Active not recruitingMerck Sharp & Dohme LLC3002024-07-162026-08-27
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Navtemadlin, Navtemadlin placebo, Ruxolitinib - Myelofibrosis, Post-PV MF
Phase 3RecruitingKartos Therapeutics, Inc.6002024-06-032025-09-25
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
Bomedemstat - Thrombocythemia, Essential, Primary Myelofibrosis
Phase 3RecruitingMerck Sharp & Dohme LLC4002024-05-232026-11-10
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
Givinostat, Hydroxyurea - Polycythemia Vera
Phase 3RecruitingItalfarmaco2202024-03-262026-03-25
Study of Olverembatinib (HQP1351) in Patients With CML-CP
olverembatinib, Bosutinib - Chronic Myeloid Leukemia, CML
Phase 3RecruitingAscentage Pharma Group Inc.3332024-02-052026-09-15
Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera
Open-label rusfertide - Polycythemia Vera
Phase 3Active not recruitingProtagonist Therapeutics, Inc.462024-01-222025-08-06
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
Bomedemstat, Anagrelide, Busulfan - Essential Thrombocythemia
Phase 3Active not recruitingMerck Sharp & Dohme LLC3402023-12-312026-10-02

Showing 20 of 233. Sign in to see all of them.

Narrower conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (85)  ·  Leukemia (71)  ·  Leukemia, Myeloid, Acute (66)  ·  Leukemia, Myeloid, Chronic-Phase (58)  ·  Primary Myelofibrosis (58)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (52)  ·  Myelodysplastic Syndromes (44)  ·  Polycythemia Vera (35)  ·  Leukemia, Myeloid, Accelerated Phase (32)  ·  Lymphoma, Non-Hodgkin (31)  ·  Thrombocythemia, Essential (31)  ·  Hodgkin Disease (30)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (30)  ·  Lymphoma (29)

Broader conditions

Hemic and Lymphatic Diseases (233)  ·  Hematologic Diseases (221)  ·  Bone Marrow Diseases (219)  ·  Neoplasms (175)  ·  Neoplasms by Histologic Type (160)  ·  Leukemia, Myeloid (151)  ·  Pathological Conditions, Signs and Symptoms (139)  ·  Chronic Disease (134)  ·  Disease Attributes (134)  ·  Pathologic Processes (134)  ·  Leukemia (92)  ·  Immune System Diseases (65)  ·  Immunoproliferative Disorders (61)  ·  Lymphatic Diseases (61)

Interventions

Imatinib Mesylate (34)  ·  Cytarabine (33)  ·  nilotinib (26)  ·  ruxolitinib (23)  ·  Hydroxyurea (20)  ·  Cyclophosphamide (19)  ·  Peripheral Blood Stem Cell Transplantation (19)  ·  Daunorubicin (18)  ·  Etoposide (18)  ·  Filgrastim (14)  ·  Busulfan (13)  ·  Methotrexate (13)  ·  Dasatinib (12)  ·  Radiotherapy (11)  ·  Mitoxantrone (10)

Sponsors

Novartis Pharmaceuticals (28)  ·  European Organisation for Research and Treatment of Cancer - EORTC (8)  ·  AOP Orphan Pharmaceuticals AG (7)  ·  Fred Hutchinson Cancer Center (7)  ·  Alliance for Clinical Trials in Oncology (6)  ·  Incyte Corporation (6)  ·  Bristol-Myers Squibb (5)  ·  Celgene (5)  ·  Children's Oncology Group (5)  ·  Merck Sharp & Dohme LLC (5)  ·  Medical College of Wisconsin (4)  ·  Eastern Cooperative Oncology Group (3)  ·  Il-Yang Pharm. Co., Ltd. (3)  ·  M.D. Anderson Cancer Center (3)  ·  Medical Research Council (3)

Countries

United States (127)  ·  Germany (75)  ·  France (72)  ·  Italy (69)  ·  Canada (65)  ·  United Kingdom (63)  ·  Spain (54)  ·  Belgium (52)  ·  Australia (49)  ·  Poland (45)  ·  Austria (44)  ·  Hungary (44)  ·  Czechia (41)  ·  Netherlands (40)  ·  Israel (39)

Top investigators

Alan K. Burnett, MD, FRCP (3)  ·  Heinz Gisslinger, MD (3)  ·  Ruediger Hehlmann, MD (3)  ·  Alan S. Gamis, MD, MPH (2)  ·  Brenda Sandmaier (2)  ·  Debra Barton, RN, PhD, AOCN, FAAN (2)  ·  Mary Horowitz, MD (2)  ·  Mary Horowitz, MD, MS (2)

Results publications

PMID 31375516, PMID 36184192, PMID 37042865, PMID 39516087, PMID 40535755, PMID 41958363, PMID 42316774, PMID 23515925, PMID 23620574, PMID 23911705, PMID 24859364, PMID 26069290, PMID 28273028, PMID 28962635, PMID 29396713, PMID 29926156, PMID 30523055, PMID 32499241, PMID 33275766, PMID 35235189, PMID 37267439, PMID 37553873, PMID 41890273, PMID 42452788, PMID 12637609, PMID 15010373, PMID 15459300, PMID 15761020, PMID 16484584, PMID 16932345, PMID 16960978, PMID 17151364, PMID 17315155, PMID 17339189, PMID 17397698, PMID 17715389, PMID 18256322, PMID 18430462, PMID 19117345, PMID 19264678, PMID 19270260, PMID 19291085, PMID 19369231, PMID 19648168, PMID 19710500, PMID 19797518, PMID 19826132, PMID 19965667, PMID 20038732, PMID 20117965

NIH funding

2023 (9), 2018 (4), 2014 (3), U01HL069294 (3), U10CA021115 (3), U10CA031946 (3), 2008 (2), 2009 (2), 2025 (2), P01CA018029 (2), P01CA078902 (2), P30CA015704 (2), P30CA068485 (2), U24CA076518 (2), 2004 (1)